S

ARS Pharmaceuticals, Inc. Common Stock

XNAS · Laboratory Analytical Instruments · S&P 500

$6.44

-$0.56 (-8.00%) today

Open $7.00 High $7.14 Low $6.42 Vol 2,933K Avg $6.60

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
PMN ProMIS Neurosciences Inc. Common Shares (ON) XNAS USD PHARMACEUTICAL PREPARATIONS
EDSA Edesa Biotech, Inc. Common Shares XNAS USD PHARMACEUTICAL PREPARATIONS
KALV KalVista Pharmaceuticals, Inc. Common Stock XNAS USD PHARMACEUTICAL PREPARATIONS
GERN Geron Corp XNAS USD PHARMACEUTICAL PREPARATIONS
TELO Telomir Pharmaceuticals, Inc. Common Stock XNAS USD PHARMACEUTICAL PREPARATIONS
XNCR Xencor, Inc. XNAS USD PHARMACEUTICAL PREPARATIONS
INO Inovio Pharmaceuticals, Inc. XNAS USD PHARMACEUTICAL PREPARATIONS
AMPH Amphastar Pharmaceuticals, Inc. XNAS USD PHARMACEUTICAL PREPARATIONS
AXSM Axsome Therapeutics, Inc XNAS USD PHARMACEUTICAL PREPARATIONS
ANNX Annexon, Inc. Common Stock XNAS USD PHARMACEUTICAL PREPARATIONS

52-week price range

$6.18 $18.63

Price is 4.2% above its 52-week low and 65.4% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

  • Primary Exchange: XNAS
  • Market Cap: 789413590.65
  • Address:
  • Category: PHARMACEUTICAL PREPARATIONS
  • Total Employees: 163
  • Listing Date: 2022-11-09